The use of subcutaneous scopolamine as a palliative treatment in Parkinson's disease.
Parkinson's disease (PD) is a degenerative, chronic and irreversible condition. Palliative medicine may play an important role in the care of patients with PD to maintain the quality of life. Scopolamine is a non-competitive antagonist at muscarinic acetylcholine receptors, which was used many years ago in the treatment for PD. To the best of our knowledge, there are no previously reported cases of the use of scopolamine for symptom relief at the end of life in patients with PD. The case reported here shows that treatment with a subcutaneous scopolamine was a useful alternative in a terminal cancer patient with severe tremors unable to take oral PD medication.
Pérez
Laura Mónica
LM
Institut Municipal d'Investigació Mèdica, Barcelona, Spain. lmperez@parcdesalutmar.cat
Farriols
Cristina
C
Puente
Victor
V
Planas
Josep
J
Ruiz
Inmaculada
I
D000368:Aged; D018680:Cholinergic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D055104:Infusions, Subcutaneous; D010166:Palliative Care; D010300:Parkinson Disease / Q000188:drug therapy*; D012601:Scopolamine / Q000008:administration & dosage / Q000627:therapeutic use*; D014202:Tremor / Q000188:drug therapy
D018680:Cholinergic Antagonists; D012601:Scopolamine